DG. Implications of using estimated glomerular filtration rate (eGFR) versus serum creatinine for identifying and referring patients with CKD. Abstract presented at UK Renal Association, Spring 2005. Available at: http://www.triangle3.org.uk/cgi-bin/ absdb/absdb_view. cgi?AbstractID=RA5305 (accessed 5th October 2005) 6 O'Donoghue DJ, Stevens P, Farmer C, De Lusignan S, Walker M. Evaluating the prevalence of chronic kidney disease in the UK using GP computerised records. Abstract presented at UK Renal Association, Spring 2004. Available at: http://www.renal.org/ Abstracts/Apr04abs.html (accessed 27th October 2005) 7 Deacon A. Limitations of estimating kidney function in adults using formulae. Ann Clin Biochem 2006; 43: 85 8 Loong T-W. Understanding sensitivity and specificity with the right side of the brain.
Comments on 'HbA 1c predicts the likelihood of having impaired glucose tolerance in high-risk patients with normal fasting plasma glucose'
In a recent article, Geberhiwot et al. 1 dealt with combining haemoglobin A 1C (HbA 1c ) and fasting plasma glucose (FPG) in high-risk populations in order to identify patients requiring an oral glucose tolerance test (OGTT), which we agree may be the best tool to detect these populations. However, in response to some of the statements and calculations in the paper, we wish to make some clarifying comments.
Firstly, there is no description of how to estimate the optimal cut-o¡ point using ROC analysis. Is it slope of the ROC curve, sensitivity, speci¢city or weighting of false positive against false negative? With their values of sensitivity (72%) and speci¢city (77%), there will still be 28% false negatives and 23% false positives, which with the number of patients in the investigation is 52 Â0.72 ¼37 true positive individuals and 173 Â0.23 ¼40 false positive individuals. Consequently, there will be more false positive than true positive individuals.
Secondly, from the text it is explained that in patients with FPGp6.0 mmol/l and HbA 1c levels o5.0%, abnormal glucose tolerance can be ruled out 'with 100% certainty'. Using the data shown in Figure 1 in their paper for HbA 1c o5.0%, the sensitivity is approximately 95%, and knowing that the total number of IGT and diabetics is 52, there are still two or three of these patients below this value, so it is not 'with 100% certainty', as concluded in their text.
Thirdly, when reporting the variability of the results, although the inter-assay coe⁄cients of variation for glucose and HbA 1c are expressed, the bias or traceability of the method is not documented. Some of us 2 used the same method to ¢nd a logarithmic distribution of HbA 1c values from a low-risk population for diabetes. In this study, the traceability is fully explained and documented, and the geometric mean of this low-risk population is 5.6% HbA 1c (i.e. half of this low-risk population would be considered quali¢ed for OGTT according to Geberhiwot et al. 1 ), so from these results it looks as though their method has an analytical bias. Therefore, the results obtained in their study would not be transferable to other laboratories, even if they are using the same method.
Finally, a minor error: they write that the results are expressed as means7SEM; however, the description of age for men is 52.9712.0 years and for women 53.3713.5. Taking into account that SEM is calculated as s/sqrt(n), the standard deviations should be129 years for men and 141 for women. Comments on 'HbA 1c predicts the likelihood of having impaired glucose tolerance in high-risk patients with normal fasting plasma glucose'
Natàlia
In a recent article, Geberhiwot et al. 1 dealt with combining haemoglobin A 1C (HbA 1c ) and fasting plasma glucose (FPG) in high-risk populations in order to identify patients requiring an oral glucose tolerance test (OGTT), which we agree may be the best tool to detect these populations. However, in response to some of the statements and calculations in the paper, we wish to make some clarifying comments. Firstly, there is no description of how to estimate the optimal cut-o¡ point using ROC analysis. Is it slope of the ROC curve, sensitivity, speci¢city or weighting of false positive against false negative? With their values of sensitivity (72%) and speci¢city (77%), there will still be 28% false negatives and 23% false positives, which with the number of patients in the investigation is 52 Â0.72 ¼37 true positive individuals and 173 Â0.23 ¼40 false positive individuals. Consequently, there will be more false positive than true positive individuals.
Finally, a minor error: they write that the results are expressed as means7SEM; however, the description of age for men is 52.9712.0 years and for women 53.3713.5. Taking into account that SEM is calculated as s/sqrt(n), the standard deviations should be129 years for men and 141 for women. Natàlia Iglesias 1 , Per Hyltoft Petersen 2 , Lone GM Jørgensen 3 and Ivan Brandslund 3, 4 Although they state that our approach may identify more false positive than true positive patients, it is generally well-recognized that with screening tests, as opposed to diagnostic tests, the proportion of a¡ected persons is likely to be small and that many positive results are likely to be false positive. 2 This ¢nding is not necessarily serious if the screening test is followed up by a con¢rmatory test such as OGTT. We believe that our approach meets the criteria set out for screening of high-risk individuals. 3, 4 Based on our data, there were 22 patients with FPG o6.0 mmol/l and HbA 1c concentration o5.0% and all of them had normal OGTT, hence our comment that in patients with FPG o6.0 mmol/l and HbA 1c o5.0%, abnormal glucose tolerance can be ruled out with 100% certainty. There was one patient with HbA 1c of 5.0% who had an abnormal OGTT and, therefore, the sensitivity at HbA 1c of 5.0% in ruling out an abnormal OGTT is 98% (which may not be clear from Figure 1 ).
We note their comment about the traceability of our method and that in their low-risk population for diabetes, using the same analytical method, the geometric mean for HbA 1c was 5.6%, suggesting that our method may have a negative analytical bias. Our method is certi¢ed and traceable to the Diabetes Control and Complications Trial (DCCT) reference method (University of Missouri, USA) and according to External Quality Assessment data (WEQAS), our results show no signi¢cant bias when compared to the same group or indeed the overall mean. However, we agree with their comment that our results or cut-o¡ levels for HbA 1c may not be transferable to other laboratories and that each laboratory must establish its own cut-o¡ levels. We acknowledge that our data were expressed as mean + SD and not as mean + SEM as stated and we thank them for pointing this out to us.
